ACTIVITIES OF 4 MACROLIDES, INCLUDING CLARITHROMYCIN, AGAINST MYCOBACTERIUM-FORTUITUM, MYCOBACTERIUM-CHELONAE, AND M-CHELONAE-LIKE ORGANISMS
ACTIVITIES OF 4 MACROLIDES, INCLUDING CLARITHROMYCIN, AGAINST MYCOBACTERIUM-FORTUITUM, MYCOBACTERIUM-CHELONAE, AND M-CHELONAE-LIKE ORGANISMS
复制标题
DOI：
10.1128/aac.36.1.180
复制
发表时间：
1992-01-01
影响因子：
4.9
通讯作者：
WALLACE, RJ
中科院分区：
文献类型：
--
作者：
BROWN, BA;WALLACE, RJ;WALLACE, RJ
采用微量肉汤稀释法比较了属于7个分类群的223株快速生长分枝杆菌对红霉素和新的大环内酯类克拉霉素的敏感性。 还对79株随机分离株进行了阿奇霉素和罗红霉素检测。 克拉霉素对90%的测试菌株的MIC（MIC 90）为0.25 μ g/ml。龟鳖虫0.5 μ g/ml;龟亚种100%的菌株受到小于或等于1 μ g/ml的抑制。 克拉霉素对M的活性是红霉素的10 - 50倍，是其他新的大环内酯类药物的4 - 8倍。龟类。 克拉霉素的MIC通常随着与M分离株孵育时间的延长而增加。龟亚种但不是M。龟亚种龟类。 克拉霉素对M.福图什湾福妥昔单抗（MIC 50，2.0 μ g/ml; MIC 90，> 8.0 μ g/ml）。 三种新的大环内酯类药物对M.福图什湾peregrinum（MIC 90为0.5 - 2.0 μ g/ml，而红霉素MIC 90> 8.0 μ g/ml）。 总的来说，克拉霉素是最有效的药物，抑制所有的M分离株。龟亚种chelonae、龟类M.龟亚种M.P.福图什湾peregrinum和M.龟类微生物和35%的M.福图什湾在小于或等于1 μ g/ml的浓度下， 新的大环内酯类药物，特别是克拉霉素，对这些环境分枝杆菌物种的临床试验似乎是必要的。
Susceptibilities to erythromycin by broth microdilution were compared with those to the newer macrolide clarithromycin for 223 isolates of rapidly growing mycobacteria belonging to seven taxonomic groups. Seventy-nine random isolates were also tested against azithromycin and roxithromycin. The MIC of clarithromycin for 90% of strains tested (MIC90) was 0.25-mu-g/ml for isolates of Mycobacterium chelonae subsp. chelonae and 0.5-mu-g/ml for M. chelonae subsp. abscessus, with 100% of strains inhibited by less-than-or-equal-to 1-mu-g/ml. Clarithromycin was 10 to 50 times more active than erythromycin and four- to eightfold more active than the other newer macrolides against M. chelonae. MICs of clarithromycin frequently increased with prolonged incubation with isolates of M. chelonae subsp. abscessus but not M. chelonae subsp. chelonae. MICs of clarithromycin were much higher for M. fortuitum bv. fortuitum (MIC50, 2.0-mu-g/ml; MIC90, > 8.0-mu-g/ml). The three newer macrolides had comparable activity against M. fortuitum bv. peregrinum (MIC90s of 0.5 to 2.0-mu-g/ml compared with erythromycin MIC90s of > 8.0-mu-g/ml). Overall, clarithromycin was the most active agent, inhibiting all isolates of M. chelonae subsp. chelonae, M. chelonae subsp. abscessus, M. fortuitum bv. peregrinum, and the M. chelonae-like organisms and 35% of M. fortuitum bv. fortuitum at less-than-or-equal-to 1-mu-g/ml. Clinical trials of the newer macrolides, especially clarithromycin, against these environmental mycobacterial species appear to be warranted.